Neurotech’s upgraded autism device gets Italcert approval
Neurotech International Limited (ASX:NTI) — developer of quality medical solutions improving the lives of children with autism — has today announced that Italcert, its independent regulator for CE compliance, has approved considerable improvements to the Mente Autism device.
With this approval, the company is now in the position to move ahead with production of the next batch of Mente Autism devices, which is expected to occur this month before releasing the product to market in Europe.
Design improvements to the next iteration of the Mente Autism device, foreshadowed in NTI’s March quarterly update, include improvements to wi-fi connectivity, synchronisation and usability linked to the firmware and the Mente Autism application.
The CE mark shows that the Mente Device complies with European health, safety and environmental protection legislation. Given this latest development, production of the next batch of the device is now underway.
CEO of Neurotech International, Wolfgang Storf said: “This is another important milestone for the company. Over the past year, we have listened to feedback from our customers and distribution partners and many of the improvements we have introduced resulted from this feedback. Our distributors are looking forward to receiving the updated device, which is expected to be available in July.”
It should be noted though that market penetration is speculative despite the updates and any investment decision in this stock should be made with caution and professional financial advice sought.
Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder.
Designed for home use, the device helps relax the minds of children on the spectrum, which in turn helps them to focus better and engage positively with their environment.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.